Potential Challenges in the Future Treatment of Mantle Cell Lymphoma

Rekha Rao, PhD
Published: Thursday, Apr 13, 2017



Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses the challenges that exist in the future of treatment for patients with mantle cell lymphoma (MCL).

One of the biggest challenges of treating patients with MCL, says Rao, is that patients eventually develop resistance to almost all therapies.

In the case of p97 inhibitors, Rao says that there should be effort dedicated to developing newer analogs of inhibitors that can work in patients who develop resistance to existing p97 inihibitors.

Rao also proposes that the combination of p97 inhibitors with ibrutinib (Imbruvica) may hold promise for patients with relapsed MCL.
 


Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses the challenges that exist in the future of treatment for patients with mantle cell lymphoma (MCL).

One of the biggest challenges of treating patients with MCL, says Rao, is that patients eventually develop resistance to almost all therapies.

In the case of p97 inhibitors, Rao says that there should be effort dedicated to developing newer analogs of inhibitors that can work in patients who develop resistance to existing p97 inihibitors.

Rao also proposes that the combination of p97 inhibitors with ibrutinib (Imbruvica) may hold promise for patients with relapsed MCL.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x